[1] 尤红, 王福生, 李太生,等. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志, 2023, 26(3): 457-478. [2] 宁会彬,靳慧鸣,李宽,等. 721例ALT正常慢性乙型肝炎患者肝脏病理炎症纤维化情况及影响因素分析. 中华肝脏病杂志,2022,26(7):746-751. [3] Zhao Q, Liu K, Zhu X, et al. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Res, 2020, 184: 104953. [4] Cheng JL, Wang XL, Yang SG, et al. Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients. World J Gastroenterol, 2017, 23(15): 2802-2810. [5] 中华医学会肝病学分会中华医学会感染病学分会 . 慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-90. [6] Tada T, Kumada T, Toyoda H, et al. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol, 2018, 33(4): 918-925. [7] Li LJ, Wu XY, Tan SW, et al. Lnc-TCL6 is a potential biomarker for early diagnosis and grade in liver-cirrhosis patients. Gastroenterol Rep (Oxf), 2019, 7(6): 434-443. [8] Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut, 2020, 69(8): 1382-1403. [9] 中华医学会肝病学分会中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版). 实用肝脏病杂志,2016,19(3):389-400. [10] Le Bert N, Gill US, Hong M, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastroenterology, 2020, 159(2): 652-664. [11] Wu Z, Ma AL, Xie Q, et al. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101463. [12] Gao WK, Shu YY, Chen Y, et al. Effectiveness of tenofovir alafenamide in chronic hepatitis B patients with normal alanine aminotransferase and positive hepatitis B virus DNA. J Clin Transl Hepatol, 2022, 10(1): 112-119. [13] 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志,2020,23(1): 161-184. [14] Yoo JJ, Park SY, Moon JE, et al. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. Clin Mol Hepatol, 2023, 29(2): 482-495. [15] Cheng TW, Yang JF, Chen YY, et al. Epidemiology of chronic hepatitis B infection in the cohort of college students with vaccination in Taiwan. Vaccines (Basel), 2023, 11(2):513-518. [16] Yang H, Bae SH, Nam H, et al. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Hepatol, 2022, 77(3): 632-641. [17] Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol, 2020, 55(4): 383-389. [18] Kawanaka M, Nishino K, Kawamoto H, et al. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol, 2021, 27(43): 7497-7508. [19] Choi GH, Lim YS. Risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Authors' reply. Aliment Pharmacol Ther, 2019, 50(5): 619-620. [20] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398. [21] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016, 10(1): 1-98. [22] Duan M, Chi X, Xiao H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int, 2021, 15(2): 318-327. [23] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63(1): 261-283. [24] Kao JH, Hu TH, Jia J, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther, 2020, 52(10): 1540-1550. [25] Choi GH, Kim GA, Choi J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther, 2019, 50(2): 215-226. |